Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8052W HIGH $3.44
Volume
646.89 K
Value Traded
7.26 M
Short % Float
21.5%
-0.93%Week
-29.61%1 Month
+21.59%3 Month
+58.52%6 Month
-91.97%5 Year
-95.2%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
163.06 M
EPS (TTM)
-0.40
P/E Ratio
-
Ent. Value
205.38 M
Total Shares
76.15 M
Float Shares
28.88 M
Insiders
62.10%
Institutions
29.79%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
STIM Catalyst Timeline
Dated clinical, regulatory and corporate events for Neuronetics, Inc.
Past FDA Catalysts and PDUFA Decisions
How STIM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 84%
Micro Cap(rank 553 of 658)
Percentile Rank
Neuronetics, Inc. faces pipeline headwinds (25/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every STIM program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Chernett Jorey10% Owner | Buy | 14,000 10,602,988 held | $3.16 | 08/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in STIM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.1 % | 911.00 K | 701.18 K |
STIM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How STIM ranks across every disease it competes in
Competitive Position is a premium feature
See how STIM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSTIM News
STIM▲ +9.1%on this news
Neuronetics and Jorey Chernett Announce Shared Vision
Neuronetics, Inc. and Jorey Chernett have established a framework for collaboration aimed at enhancing shareholder value. Chernett, a significant shareholder, expressed confidence in the company's financial health and management. He will have the opportunity to recommend a new Board member to further align shareholder interests with corporate strategy.
Read more →STIM▲ +9.1%on this newsshared move
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics, Inc. announced the granting of inducement awards to five new non-executive employees in compliance with NASDAQ Listing Rule 5635(c)(4). These awards are part of the company's 2020 Inducement Incentive Plan and are contingent on the employees' continued service. Neuronetics is recognized for its innovative NeuroStar® TMS technology and extensive network of interventional psychiatry clinics.
Read more →STIMNeuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. plans to announce its second quarter 2026 financial results on August 11, 2026, prior to market opening. A conference call will follow at 8:30 a.m. Eastern Time to discuss the results. The company is known for its NeuroStar TMS technology and operates a significant network of interventional psychiatry clinics.
Read more →STIM▼ -6.9%on this news
Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
Neuronetics has appointed Nir Naor as Chief Financial Officer, effective July 23, 2026, bringing extensive finance experience. Cory Anderson has been promoted to Executive Vice President and General Manager of Greenbrook, effective July 1, 2026. Andrew Macan will step down as Chief Legal Officer on August 15, 2026. These changes reflect the company's strategic growth in interventional mental health.
Read more →STIM▲ +10.6%on this news
Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
Neuronetics, Inc. will participate in the B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026. The event will feature a panel discussion on commercializing novel neuropsychiatric drugs, alongside Compass Pathways. Management will also hold one-on-one meetings with institutional investors, although there will be no live webcast of the discussion.
Read more →STIM▼ -6.6%on this news· ran to -23% by day 3
Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026
Neuronetics, Inc. is participating as a Silver Sponsor at the 2026 Clinical TMS Society Annual Meeting, where it will present real-world data from its TrakStar database. The presentations will focus on the effectiveness of transcranial magnetic stimulation (TMS) for mental health conditions, including major depressive disorder. This participation underscores Neuronetics' commitment to advancing TMS research and evidence-based treatment options.
Read more →STIM▼ -6.6%on this news· ran to -23% by day 3shared move
Neuronetics Appoints Robert Greene as Senior Vice President Sales
Neuronetics, Inc. has appointed Robert Greene as Senior Vice President Sales, effective June 1, 2026. Greene brings significant experience in leading sales organizations within the healthcare sector. His appointment is expected to enhance Neuronetics' commercial strategy and sales efforts, particularly in neurohealth products.
Read more →STIM▼ -13.9%on this news
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
Neuronetics, Inc. announced a strategic partnership with ANT Neuro to integrate advanced neuronavigation technology into its NeuroStar Advanced Therapy System. This collaboration will enhance treatment delivery by incorporating real-time spatial tracking and 3D visualization, aimed at improving patient outcomes in neurohealth disorders. The partnership will be showcased at upcoming industry meetings, with a broader rollout planned for the latter half of 2026. The integration seeks to meet the evolving needs of healthcare providers in the TMS market.
Read more →STIM▲ +7.4%on this news· ran to -18% by day 3
Neuronetics Reports First Quarter 2026 Financial and Operating Results
Neuronetics, Inc. reported its first quarter 2026 financial results, showing an 8% revenue increase to $34.5 million compared to the previous year. The company also noted a significant reduction in cash used for operations and an expansion of its TMS clinical policy, which broadens treatment access. However, the net loss for the quarter was $10.8 million, and gross margins decreased slightly.
Read more →STIM▼ -5.1%on this news
Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. will release its first quarter 2026 financial results on May 5, 2026, before market open. A conference call to discuss these results will follow at 8:30 a.m. ET. The company focuses on improving the quality of life for patients with neurohealth disorders through its NeuroStar Advanced Therapy.
Read more →STIMOptum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners
Neuronetics, Inc. announced that Optum/United Healthcare/United Behavioral Health has expanded its TMS policy to allow psychiatric mental health nurse practitioners to order and administer NeuroStar therapy. This change enhances access to treatment for millions of patients across 26 states and Washington, D.C. The update recognizes the vital role of nurse practitioners in mental healthcare, particularly for those who have not responded to traditional medications.
Read more →STIM▼ -10.2%on this news· ran to -23% by day 3
Neuronetics Announces Chief Financial Officer Transition
Neuronetics, Inc. has announced the departure of CFO Steven E. Pfanstiel, who will leave to pursue another opportunity. He will assist in the transition until May 1, 2026. The company has reaffirmed its financial guidance for the fiscal year 2026, emphasizing its commitment to improving mental health treatment options.
Read more →STIM▼ -10.2%on this news· ran to -23% by day 3shared move
Neuronetics Comments on Letter from Pointillist Family Office
Neuronetics, Inc. responded to a letter from Jorey Chernett of Pointillist Family Office, emphasizing its commitment to maximizing shareholder value. The Board appreciates shareholder engagement and agrees that the company's current valuation does not fully reflect its business strength. Neuronetics aims to enhance long-term value through strategic priorities.
Read more →STIM▲ +15.8%on this newsshared move
Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business
Jorey Chernett, the largest independent shareholder of Neuronetics, has urged the Board to conduct a comprehensive review of strategic alternatives, including the potential sale of the TMS business. Chernett believes that separating the TMS and clinic businesses could unlock significant shareholder value, estimating a 5-7x increase in equity value. He emphasizes that the anticipated synergies from the merger have not been realized, and that a focused approach could enhance the clinic business's performance.
Read more →STIM▼ -9.9%on this news
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Neuronetics reported a strong financial performance for Q4 and full year 2025, with total revenue increasing significantly, driven by the acquisition of Greenbrook TMS. The company appointed Dan Reuvers as CEO, aiming to leverage his experience for future growth. Despite a net loss, operational cash flow improved, and the company anticipates continued revenue growth in 2026.
Read more →STIM▼ -9.9%on this newsshared move
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
Neuronetics, Inc. has appointed Dan Reuvers as the new President and CEO, effective March 23, 2026. Reuvers, who has over three decades of experience in medical technology, succeeds Keith Sullivan, who is retiring after five and a half years. The Board expressed confidence in Reuvers' ability to drive growth and expand treatment access for patients suffering from neurohealth disorders.
Read more →STIMNeuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. plans to release its fourth quarter 2025 financial results on March 17, 2026, prior to market opening. A conference call will follow at 8:30 a.m. ET to discuss these results. The company focuses on innovative neurohealth therapies, including the NeuroStar Advanced Therapy, aimed at improving mental health outcomes.
Read more →STIM▲ +23.3%on this news
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
Neuronetics, Inc. reported strong preliminary unaudited financial results for Q4 and full year 2025, with revenues reaching $41.8 million and $149.2 million respectively. The company experienced significant growth in both NeuroStar and clinic revenues, alongside positive operating cash flow. The results reflect successful commercial execution and increased demand for their neurohealth therapies.
Read more →STIM▼ -12.8%on this news
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
Neuronetics, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025. The management team will engage in a fireside chat at 12:30 p.m. ET, which will be accessible to registered attendees. Neuronetics is recognized for its innovative neurohealth therapies, particularly the NeuroStar Advanced Therapy System.
Read more →About Neuronetics, Inc.
Headquarters3222 PHOENIXVILLE PIKE, MALVERN, PA, 19355
BIOPHARMAWATCH ELITE PLUS
Trade the next STIM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime